We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The Centers for Medicare & Medicaid Services (CMS) is guilty of fostering a monopoly in the treatment of anemia and may also be placing the public in jeopardy through its policies, lawmakers say.
The Centers for Medicare & Medicaid Services (CMS) is guilty of fostering a monopoly in the treatment of anemia and may also be placing the public in jeopardy through its policies, lawmakers say.
Congressional Democrats’ plan to have the federal government directly negotiate for lower Medicare drug costs will take a major hit because of estimates that the current program will be more than $117 billion under budget over the next 10 years, a Centers for Medicare & Medicaid Services (CMS) source said. Read More
Congressional Democrats' plan to have the federal government directly negotiate for lower Medicare drug costs will take a major hit because of estimates that the current program will be more than $117 billion under budget over the next 10 years, a Centers for Medicare & Medicaid Services (CMS) source said. Read More
Conservative and moderate House Democrats, known as “Blue Dog” Democrats, represent a pivotal voting bloc that will help decide what healthcare legislation makes it through the House and whether the White House and Democratic leadership can reach compromises, former lawmakers and Hill staffers say.
Conservative and moderate House Democrats, known as “Blue Dog” Democrats, represent a pivotal voting bloc that will help decide what healthcare legislation makes it through the House and whether the White House and Democratic leadership can reach compromises, former lawmakers and Hill staffers say.
Industry groups are criticizing a recent activist report on the state of the Medicare prescription drug plan as a ploy to get direct government negotiation of Medicare costs, a move which they say will limit consumers’ choices.
The long and controversial Plan B approval may by over for Barr Pharmaceuticals, but trouble for the Bush administration over its handling of the matter continues.
A class action claim alleging widespread Medicare fraud by the pharmaceutical industry headed to trial last week after a federal district court denied an industry motion to dismiss the suit.